Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US76029N1063
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00L8Z22R1
REPL
Replimune Group Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Replimune Group Inc
ISIN
US76029N1063
TICKER
REPL
MIC
XNAS
REUTERS
REPL.OQ
BLOOMBERG
REPL US
Sa., 06.09.2025       Replimune Group
US76029N1063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Sa., 06.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclus...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Fr., 05.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The law...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Do., 04.09.2025       Replimune Group
US76029N1063

The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REPL during the...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Do., 04.09.2025       Replimune Group
US76029N1063

SAN FRANCISCO, Sept. 4, 2025 /PRNewswire/ -- A new securities class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and its executives. The lawsuit alleges that the company misled investors by overstating the success of its lead cancer drug, RP1, leading to a massive 77% stock price crash after the FDA rejected its appl...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Do., 04.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 4, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mi., 03.09.2025       Replimune Group
US76029N1063

SAN FRANCISCO, Sept. 3, 2025 /PRNewswire/ -- Replimune Group Inc. (NASDAQ: REPL) is under fire from investors following a dramatic regulatory setback that sent its stock into freefall. A newly filed securities class action accuses the biotech firm and its leadership of concealing critical risks tied to its flagship cancer therapy, RP1, and overst...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mi., 03.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail a...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mi., 03.09.2025       Replimune Group
US76029N1063

LOS ANGELES, Sept. 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mi., 03.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclus...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 02.09.2025       Replimune Group
US76029N1063

RADNOR, Pa., Sept. 2, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Replimune Group, Inc. ("Replimune") (NASDAQ: REPL) on behalf of those who purchased or otherwise acquired Replimune securities between November 22, 2024, a...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Di., 02.09.2025       Replimune Group
US76029N1063

NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The law...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Di., 02.09.2025       Replimune Group
US76029N1063

LOS ANGELES, Sept. 1, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Fr., 29.08.2025       Replimune Group
US76029N1063

SAN DIEGO, Aug. 28, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between November 22, 2024 and July 21, 2025. Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development an...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mi., 27.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 27, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclu...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Di., 26.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The law...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Di., 26.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail a...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mo., 25.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Sa., 23.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclus...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Fr., 22.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail a...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 22.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The law...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Di., 19.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The law...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mo., 18.08.2025       Replimune Group
US76029N1063

LOS ANGELES, Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Sa., 16.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail a...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Fr., 15.08.2025       Replimune Group
US76029N1063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Fr., 15.08.2025       Replimune Group
US76029N1063

RADNOR, Pa., Aug. 15, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Replimune Group, Inc. ("Replimune") (NASDAQ: REPL) on behalf of those who purchased or otherwise acquired Replimune securities between November 22, 2024,...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Fr., 15.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The law...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Do., 14.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclus...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Do., 14.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mi., 13.08.2025       Replimune Group
US76029N1063

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Replimune Group, Inc. (“Replimune”) (NASDAQ: REPL) on behalf of those who purchased or otherwise acquired Replimune securities between November 22, 2024, and July 21, 2025, inclusive (the “Class Peri...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Di., 12.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The law...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mo., 11.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail a...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mo., 11.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mo., 11.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 11, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all persons or entities who purchased the securities of Replimune Group, Inc. (NASDAQ: REPL) ("Replimune" or the "Company")...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Sa., 09.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 9, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclus...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Sa., 09.08.2025       Replimune Group
US76029N1063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Replimune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Fr., 08.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The laws...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Do., 07.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL). Shareholders who purchased shares of REPL during the class period listed are encouraged...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Do., 07.08.2025       Replimune Group
US76029N1063

WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended June 30, 2025 and provided a business update....
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Fr., 01.08.2025       Replimune Group
US76029N1063

NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The laws...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Do., 31.07.2025       Replimune Group
US76029N1063

LOS ANGELES, July 31, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Do., 31.07.2025       Replimune Group
US76029N1063

NEW YORK, July 31, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail a...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Di., 29.07.2025       Replimune Group
US76029N1063

NEW YORK, July 29, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between Nov...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Di., 29.07.2025       Replimune Group
US76029N1063

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Faru...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mo., 28.07.2025       Replimune Group
US76029N1063

NEW YORK, July 28, 2025 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) and certain of its officers....
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Mo., 28.07.2025       Replimune Group
US76029N1063

LOS ANGELES, July 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
So., 27.07.2025       Replimune Group
US76029N1063

NEW YORK, July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   ...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
So., 27.07.2025       Replimune Group
US76029N1063

NEW YORK, July 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail a...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Fr., 25.07.2025       Replimune Group
US76029N1063

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Replimune, you are encouraged to obtain additional information by visiting: http...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink
Fr., 25.07.2025       Replimune Group
US76029N1063

LOS ANGELES, July 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by t...
Zur Nachricht
Replimune Group
Charts & Research Termsheets Terminal
Permalink